UK Prostate Cancer Diagnostics Market Size & Outlook
UK prostate cancer diagnostics market, 2018-2030 (US$M)
Related Markets
UK prostate cancer diagnostics market highlights
- The UK prostate cancer diagnostics market generated a revenue of USD 390.8 million in 2023 and is expected to reach USD 673.2 million by 2030.
- The UK market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Prostate cancer diagnostics market data book summary
| Market revenue in 2023 | USD 390.8 million |
| Market revenue in 2030 | USD 673.2 million |
| Growth rate | 8.1% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
| Key market players worldwide | MDxHealth SA, Myriad Genetics Inc, Abbott Laboratories, Roche Holding AG, Bayer AG, Siemens Healthineers AG ADR, OPKO Health Inc, Exact Sciences Corp, Pfizer Inc |
Other key industry trends
- In terms of revenue, UK accounted for 5.1% of the global prostate cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany prostate cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 673.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Diagnostics Market Scope
Prostate Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK prostate cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.82% in 2023. Horizon Databook has segmented the UK prostate cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Each year, in the UK, out of 47,600 cases of prostate cancer, approximately 11,600 deaths are reported. The average age of a patient is 65–69. As per National Screening Committee (UK NSC), an increased PSA level can indicate presence of prostate cancer, although there is evidence showing PSA test miss leading to risk of cancer.
It can falsely identify the presence of prostate cancer or find symptoms. This results in unnecessary treatments with side effects. Therefore, UK NSC has set no national screening guidelines since there were no reliable tests to be employed. Although PSA testing is free for people aged 50 or more; it is recommended to understand the pros & cons of the testing from a general practitioner.
Reasons to subscribe to UK prostate cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK prostate cancer diagnostics market databook
-
Our clientele includes a mix of prostate cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK prostate cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UK prostate cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK prostate cancer diagnostics market size, by end use, 2018-2030 (US$M)
UK Prostate Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
